Cancer drug pertuzumab tested for Long-Term use in extension trial

NCT ID NCT02320435

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease worsens or side effects become too severe. Researchers will track how long patients live without their cancer growing, overall survival, and any side effects over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pertuzumab (Perjeta), sometimes with trastuzumab or other anti-cancer drugs
What this could lead to: If successful, this study could confirm that long-term pertuzumab treatment is safe and effective for controlling certain solid tumors.
What could go wrong: This is an extension study with no control group, so results are limited. Side effects like heart problems or liver injury are possible, and not all patients may benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

A.O. Universitaria Pisana

Pisa, Tuscany, 56100, Italy
AUSL ? IRCCS Santa Maria Nuova

Reggio Emilia, Emilia-Romagna, 42100, Italy
Asan Medical Center

Seoul, 05505, South Korea
Asst Di Monza

Monza, Lombardy, 20052, Italy
Az. Osp. S. Orsola Malpighi

Bologna, Emilia-Romagna, 40138, Italy
Beijing Cancer Hospital

Beijing, 100142, China
CENEIT Oncologicos

Mexico City, 03100, Mexico
Cancerologia de Queretaro

Querétaro City, Querétaro, 76090, Mexico
Centre Georges Francois Leclerc

Dijon, 21079, France
Centre Henri Becquerel

Rouen, 76038, France
Centre Rene Huguenin

Saint-Cloud, 92210, France
Clinica Anglo Americana - Centro de Investigacion Oncologia CAA

Lima, L27, Peru
Clinica Internacional, Sede San Borja

Lima, Lima 41, Peru
Clinique Armoricaine Radiologie

Saint-Brieuc, 22015, France
Fudan University Shanghai Cancer Center

Shanghai, 200032, China
Fudan University Shanghai Cancer Center

Shanghai, 200120, China
Gifu University Hospital

Gifu, 501-1194, Japan
Harbin Medical University Cancer Hospital

Harbin, 150081, China
Hospital Amaral Carvalho

Jaú, São Paulo, 17210-080, Brazil
Hospital Metropolitano (Sede Lindora-Santa Ana)

San José, 10903, Costa Rica
Hospital Nacional Carlos Alberto Seguin Escobedo-Essalud

Arequipa, 04001, Peru
Hospital Perola Byington

São Paulo, São Paulo, 01317-000, Brazil
Hospital Sírio-Libanês

São Paulo, São Paulo, 01308-050, Brazil
Hospital Universitari i Politecnic La Fe

Valencia, 46026, Spain
Hospital Universitario Marques de Valdecilla

Santander, Cantabria, 39008, Spain
Hospital Universitario de Canarias

San Cristóbal de La Laguna, Tenerife, 38320, Spain
Hospital da Luz

Lisbon, 1500-650, Portugal
Hospital de Basurto

Bilbao, Vizcaya, 48013, Spain
Hospital de Santa Maria

Lisbon, 1649-035, Portugal
Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus

Frankfurt am Main, 60389, Germany
ICO L'Hospitalet

L'Hospitalet de Llobregat, Barcelona, 08908, Spain
IPO de Coimbra

Coimbra, 3000-075, Portugal
IPO do Porto

Porto, 4200-072, Portugal
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola

Meldola, Emilia-Romagna, 47014, Italy
Iem-Fucam

D.F., Mexico CITY (federal District), 04980, Mexico
Instituto Nacional de Cancer - INCa

Rio de Janeiro, 20560-120, Brazil
Instituto Nacional de Cancerologia

Distrito Federal, 14080, Mexico
Instituto de Oncologia de Sorocaba - CEPOS

Sorocaba, São Paulo, 18030-005, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP

São Paulo, São Paulo, 01246-000, Brazil
Irccs Ist. Tumori Giovanni Paolo Ii

Bari, Apulia, 70124, Italy
Irccs Istituto Europeo Di Oncologia (IEO)

Milan, Lombardy, 20141, Italy
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)

Nanjing, 210029, China
Kursk Regional Clinical Oncology Dispensary

Kursk, 305035, Russia
Liaoning cancer Hospital & Institute

Shenyang, 110042, China
Mun. Multifield Clin.Hosp.#4,Dept. of Chemotherapy, DSMU

Dnipropetrovsk, 49102, Ukraine
National Cancer Center Hospital East

Chiba, 277-8577, Japan
Núcleo de Pesquisa São Camilo

São Paulo, São Paulo, 04014-002, Brazil
Onkologische Praxis Neumarkt (Dr. med. Ekkehart Ladda)

Neumarkt, 92318, Germany
Praxis für Ambulante Onkologie im Krankenhaus Jerusalem

Hamburg, 20357, Germany
Praxis für Interdisziplinäre Onkologie und Hämatologie GbR

Freiburg im Breisgau, 79110, Germany
SBI of Healthcare Samara Regional Clinical Oncology Dispensary

Samara, 443031, Russia
Saitama Cancer Center

Saitama, 362-0806, Japan
Samodzielny Publiczny Kliniczny Nr 1 W Lublinie

Lublin, 20-081, Poland
Santa Casa de Misericordia de Porto Alegre

Porto Alegre, Rio Grande do Sul, 90050-170, Brazil
Seoul National University Hospital

Seoul, 03080, South Korea
Severance Hospital, Yonsei University Health System

Seoul, 03722, South Korea
State Oncology Regional Treatment-Diagnostic Center

Lviv, 79031, Ukraine
Studienzentrum UnterEms;Onkologische Schwerpunktpraxis Leer

Leer, 26789, Germany
The First Hospital of Jilin University

Changchun, 130021, China
Vall d'Hebron Institute of Oncology (VHIO), Barcelona

Barcelona, 08035, Spain
West China Hospital, Sichuan University

Chengdu, 610041, China
Zhejiang Cancer Hospital

Hangzhou, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.